18 completed. 14 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 14 |
| Not applicable | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Sodium Dodecyl Sulfate: new trials by email Literature Review of Sodium Dodecyl Sulfate trials Research Report on Sodium Dodecyl Sulfate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Excipient Effect on Drug Absorption in Humans Fexofenadine Hydrochloride without sodium lauryl sulfate, Fexofenadine Hydrochloride with sodium lauryl sulfate - The Impact of Excipients on Drug Absorption | Early Phase 1 | Completed | University of California, San Francisco | 12 | 2023-01-31 | 2025-11-18 |
| A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers SM04755, Vehicle, White Petrolatum - Tendinopathy | Phase 1 | Completed | Biosplice Therapeutics, Inc. | 223 | 2017-09-11 | 2026-10-01 |
| A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%, Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%, Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% - Dermatitis | Not applicable | Completed | Kimberly-Clark Corporation | 24 | 2015-11-01 | 2016-09-28 |
| Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers M518101, M518101 Vehicle, Sodium lauryl sulfate - Healthy Volunteers | Phase 1 | Completed | Maruho North America Inc. | 240 | 2014-09-01 | 2015-08-11 |
| Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers M518101, M518101 Vehicle, sodium lauryl sulfate - Healthy Volunteers | Phase 1 | Completed | Maruho North America Inc. | 30 | 2014-09-01 | 2015-03-30 |
| Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth 2% CHG Cloth solution, Vehicle Cloth, Active Comparator - Surgery | Phase 3 | Completed | Medline Industries | 249 | 2014-08-01 | 2017-03-09 |
| 21 Day Cumulative Skin Irritation of RUT058-60 Hypochlorous acid solution 106 mg/L, 0.1% (w/v) Sodium Lauryl Sulfate, 0.9% Physiological Saline, USP - Irritation/Irritant | Phase 1 | Completed | Pulmatrix Inc. | 43 | 2014-07-01 | 2016-02-04 |
| A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel 1% Diclofenac Sodium, 3% Menthol, 0.09% Menthol - Pain | Phase 1 | Completed | GlaxoSmithKline | 36 | 2014-06-01 | 2017-06-29 |
| Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA ChloraPrep, 0.1% Sodium Lauryl Sulfate, 0.9% Physiological Saline - Surgical Site Infection | Phase 1 | Completed | Zurex Pharma, Inc. | 40 | 2014-06-01 | 2014-10-27 |
| Dermal Tolerability of Dapsone Gel in Healthy Volunteers dapsone gel, dapsone gel vehicle, sodium lauryl sulfate - Healthy Volunteers | Phase 1 | Completed | Almirall, S.A. | 237 | 2014-04-01 | 2018-10-09 |
| Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9% - Head Lice | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 40 | 2014-01-01 | 2021-07-26 |
| Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate, saline 0.9% - Head Lice | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 238 | 2014-01-01 | 2020-04-29 |
| 21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water - Healthy | Phase 1 | Completed | LEO Pharma | 40 | 2011-09-01 | 2020-04-01 |
| A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804 PH-797804 material sparing tablet, PH-797804 Phase2b/3 with sodium lauryl sulphate, PH-797804 Phase2b/3 without sodium lauryl sulphate - Healthy | Phase 1 | Completed | Pfizer | 18 | 2010-11-01 | 2011-03-10 |
| Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis sodium lauryl sulfate - Recurrent Aphthous Stomatitis | Not applicable | Completed | Yonsei University | 90 | 2010-01-01 | 2011-12-29 |
| Cumulative Irritation Test AN2718, Sodium Lauryl Sulfate - Tinea Pedis | Phase 1 | Completed | Pfizer | 44 | 2008-10-01 | 2019-04-16 |
| Cumulative Irritation Test AN2690, AN2690 Solution, Vehicle, Sodium Lauryl Sulfate, 0.5% - Onychomycosis | Phase 1 | Completed | Pfizer | 37 | 2007-01-22 | 2019-04-09 |
| Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects BILR 355 BS /1B, current low dose formulation, BILR 355 BS /1B, current high dose formulation, BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 88 | 2005-06-01 | 2018-08-31 |
Pain (2) · Dermatitis (1) · Onychomycosis (1) · Stomatitis, Aphthous (1) · Surgical Wound Infection (1) · Tendinopathy (1) · Tinea Pedis (1)
Pfizer (3) · Dr. Reddy's Laboratories Limited (2) · Maruho North America Inc. (2) · Almirall, S.A. (1) · Biosplice Therapeutics, Inc. (1) · Boehringer Ingelheim (1) · GlaxoSmithKline (1) · Kimberly-Clark Corporation (1) · LEO Pharma (1) · Medline Industries (1) · Pulmatrix Inc. (1) · University of California, San Francisco (1) · Yonsei University (1) · Zurex Pharma, Inc. (1)
United States (15) · Singapore (1)
Jonathan Dosik (2) · Barry Reece, MBA (1) · Esther Campbell (1) · J Pullman, MD (1) · Jeong-Seung Kwon (1) · John Pullman, M.D. (1) · Katherine Yang, PharmD, MPH (1) · Yusuf Yazici, M.D. (1)